Activated thrombin-activatable fibrinolysis inhibitor attenuates spontaneous fibrinolysis of batroxobin-induced fibrin deposition in rat lungs

Summary

Studies have shown that inhibition of TAFI by small peptides enhances pharmacological effects of tPA in animal models of thrombosis, suggesting that TAFI modulates the fibrinolytic system. In this study, we investigated the effect of activated human TAFI (TAFIa) on endogenous fibrinolysis in a rat model of intravascular fibrin deposition. ¹²⁵I-labeled fibrinogen was injected intravenously followed by a bolus injection of batroxo-bin, a thrombin-like enzyme. Batroxobin cleaved fibrinogen to form insoluble fibrin that was deposited in tissues, including the lungs. This was shown by a decrease of radioactivity in the blood as a result of consumption of ¹²⁵I-labeled fibrinogen and an elevation of radioactivity in the lungs 5 min following batroxobin administration. Endogenous fibrinolysis was detected by a gradual increase in radioactivity in the blood and a decrease in radioactivity in the lungs at 30 min, an indication of radio-labeled fibrin degradation products (FDPs) being released into the circulation from the tissues. Intravenous administration of human TAFIa dose-dependently attenuated the later phase reduction of radioactivity in the lungs. When the dose of TAFIa was 218 μg/kg, giving a peak plasma level of TAFIa 0.9 ± 0.05 μg/ml, the spontaneous fibrinolysis was completely prevented. These results provide direct evidence that an increase in circulating TAFIa impairs endogenous clot lysis in a rat model of fibrin deposition.

Keywords

TAFI - PAI-1 - batroxobin - fibrinolysis - rat - lung fibrin deposition

• References

• 1 Collen D, Lijnen HR. Basic and clinical aspects of fibrinolysis and thrombolysis. Blood 1991; 78: 3114-24.
• 2 Vassalli JD, Sappino AP, Belin D. The plasminogen activator/plasmin system. J Clin Invest 1991; 88: 1067-72.
• 3 Nesheim M, Wang W, Boffa M, Nagashima M, Morser J, Bajzar L. Thrombin, thrombomodulin and TAFI in the molecular link between coagulation and fibrinolysis. Thromb Haemost 1997; 78: 386-91.
• 4 Sakharov DV, Plow EF, Rijken DC. On the mechanism of the antifibrinolytic activity of plasma carboxypeptidase B. J Biol Chem 1997; 272: 14477-82.
• 5 Bajzar L, Nesheim M, Morser J, Tracy PB. Both cellular and soluble forms of thrombomodulin inhibit fibrinolysis by potentiating the activation of thrombin-activable fibrinolysis inhibitor. J Biol Chem 1998; 273: 2792-8.
• 6 Bajzar L, Morser J, Nesheim M. TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex. J Biol Chem 1996; 271: 16603-8.
• 7 Bajzar L, Manuel R, Nesheim ME. Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor. J Biol Chem 1995; 270: 14477-84.
• 8 Lin JH, McLean K, Morser J. et al. Modulation of glycosaminoglycan addition in naturally expressed and recombinant human thrombomodulin. J Biol Chem 1994; 269: 25021-30.
• 9 Wang W, Nagashima M, Schneider M, Morser J, Nesheim M. Elements of the Primary Structure of Thrombomodulin Required for Efficient Thrombin-activable Fibrinolysis Inhibitor Activation. J Biol Chem 2000; 275: 22942-47.
• 10 Lenfors S, Gustafsson D. New model for in vivo studies of pharmacological interventions with endogenous fibrinolysis: effects of thrombin inhibitors. Semin Thromb Hemost 1996; 22: 335-42.
• 11 Abrahamsson T, Nerme V, Stromqvist M. et al. Anti-thrombotic effect of a PAI-1 inhibitor in rats given endotoxin. Thromb Haemost 1996; 75: 118-26.
• 12 Bell Jr WR. Defibrinogenating enzymes. Drugs 1997; 54: 18-30. discussion 30-1
• 13 Pirkle H, Stocker K. Thrombin-like enzymes from snake venoms: an inventory. For the Subcommittee on Nomenclature of Exogenous Hemostatic Factors of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 1991; 65: 444-50.
• 14 Pizzo SV, Schwartz ML, Hill RL, McKee PA. Mechanism of ancrod anticoagulation. A direct proteolytic effect on fibrin. J Clin Invest 1972; 51: 2841-50.
• 15 Regoeczi E, Gergely J, McFarlane AS. In vivo effects of Agkistrodon rhodostoma venom: studies with fibrinogen-131I. J Clin Invest 1966; 45: 1202-12.
• 16 Klocking HP, Markwardt F, Guttner J. On the mechanism of batroxobin-induced fibrinolysis. Pharmazie 1989; 44: 504-5.
• 17 Redlitz A, Tan AK, Eaton DL, Plow EF. Plasma carboxypeptidases as regulators of the plasminogen system. J Clin Invest 1995; 96: 2534-8.
• 18 Minnema MC, Friederich PW, Levi M. et al. Enhancement of rabbit jugular vein thrombolysis by neutralization of factor XI. In vivo evidence for a role of factor XI as an anti-fibrinolytic factor. J Clin Invest 1998; 101: 10-4.
• 19 Gresele P, Momi S, Berrettini M. et al. Activated human protein C prevents thrombin-induced thromboembolism in mice. Evidence that activated protein c reduces intravascular fibrin accumulation through the inhibition of additional thrombin generation. J Clin Invest 1998; 101: 667-76.
• 20 Nagashima M, Yin ZF, Zhao L. et al. Thrombin-activatable fibrinolysis inhibitor (TAFI) deficiency is compatible with murine life. J Clin Invest 2002; 109: 101-10.
• 21 Swaisgood CM, Schmitt D, Eaton D, Plow EF. In vivo regulation of plasminogen by plasma carboxypeptidase B. J Clin Invest 2002; 110: 1275-82.
• 22 Stromqvist M, Schatteman K, Leurs J. et al. Immunological assay for the determination of procarboxypeptidase U antigen levels in human plasma. Thromb Haemost 2001; 85: 12-7.
• 23 van Tilburg NH, Rosendaal FR, Bertina RM. Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis. Blood 2000; 95: 2855-9.
• 24 Loskutoff DJ, Sawdey M, Mimuro J. Type 1 plasminogen activator inhibitor. Prog Hemost Thromb 1989; 9: 87-115.
• 25 Sprengers ED, Kluft C. Plasminogen activator inhibitors. Blood 1987; 69: 381-7.
• 26 Krishnamurti C, Barr CF, Hassett MA, Young GD, Alving BM. Plasminogen activator inhibitor: a regulator of ancrod-induced fibrin deposition in rabbits. Blood 1987; 69: 798-803.
• 27 Carmeliet P, Stassen JM, Schoonjans L, Ream B. et al. Plasminogen activator inhibitor-1 gene-deficient mice. II. Effects on hemostasis, thrombosis, and thrombolysis. J Clin Invest 1993; 92: 2756-60.
• 28 Suffredini AF, Harpel PC, Parrillo JE. Promotion and subsequent inhibition of plasminogen activation after administration of intravenous endotoxin to normal subjects. N Engl J Med 1989; 320: 1165-72.
• 29 Emeis JJ, Kooistra T. Interleukin 1 and lipopolysaccharide induce an inhibitor of tissue-type plasminogen activator in vivo and in cultured endothelial cells. J Exp Med 1986; 163: 1260-6.
• 30 Padro T, Quax PH, van den Hoogen CM, Roholl P, Verheijen JH, Emeis JJ. Tissue-type plasminogen activator and its inhibitor in rat aorta. Effect of endotoxin. Arterioscler Thromb 1994; 14: 1459-65.
• 31 Levi M, ten Cate H, Bauer KA. et al. Inhibition of endotoxin-induced activation of coagulation and fibrinolysis by pentoxifylline or by a monoclonal anti-tissue factor antibody in chimpanzees. J Clin Invest 1994; 93: 114-20.
• 32 Nilsson IM, Ljungner H, Tengborn L. Two different mechanisms in patients with venous thrombosis and defective fibrinolysis: low concentration of plasminogen activator or increased concentration of plasminogen activator inhibitor. Br Med J (Clin Res Ed) 1985; 290: 1453-6.
• 33 Aillaud MF, Juhan-Vague I, Alessi MC. et al. Increased PA-inhibitor levels in the postoperative period—no cause-effect relation with increased cortisol. Thromb Haemost 1985; 54: 466-8.
• 34 Paramo JA, Colucci M, Collen D, van de Werf F. Plasminogen activator inhibitor in the blood of patients with coronary artery disease. Br Med J (Clin Res Ed) 1985; 291: 573-4.
• 35 Colucci M, Paramo JA, Collen D. Generation in plasma of a fast-acting inhibitor of plasminogen activator in response to endotoxin stimulation. J Clin Invest 1985; 75: 818-24.
• 36 Folsom AR, Aleksic N, Park E, Salomaa V, Juneja H, Wu KK. Prospective study of fibrinolytic factors and incident coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study. Arterioscler Thromb Vasc Biol 2001; 21: 611-7.